Eli Lilly and Company (LLY)
Eli Lilly: The Weight-Loss Leader With More Upside If Execution Holds
Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top- and bottom-line growth, reinforcing its bullish long-term outlook. The company offers stability amid market volatility, with strong U.S. dominance, premium margins, and potential undervaluation if growth targets are met.
When Investors Panic, I Buy Eli Lilly
Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and upcoming orforglipron, drives robust international growth and pipeline expansion. Massive manufacturing investments and a deep late-stage pipeline, including orforglipron and retatrutide, reinforce LLY's durable competitive moat.
Eli Lilly becomes first health-care company to hit $1 trillion
Silicon Valley's giants crowd the list of the world's most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of one trillion dollars on Friday, becoming the first business in the health industry to hit that milestone.
Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Eli Lilly first healthcare company to hit $1T market capitalization
Eli Lilly and Co (NYSE:LLY) briefly reached a market capitalization of $1 trillion during trading on Friday, making it the first healthcare company to achieve this milestone. Shares of the Indianapolis-based drugmaker rose as much as 1.7% just shy of $1,060, bringing its market value to roughly $1 trillion before retreating slightly, with stock trading near $1,050 per share later in the session.
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
November's Wall Street obsession hasn't been AI. It's been healthcare.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Weight-loss drugmaker Eli Lilly hit a $1 trillion market cap, joining a select group of mostly tech companies
Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.
Eli Lilly hits $1 trillion market value, a first for a health-care company
Drugmaker Eli Lilly reached a $1 trillion market capitalization, the first health-care company in the world to join the exclusive club dominated by tech firms. The pharmaceutical giant's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly Stock To $1,330?
Eli Lilly's stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally is fueled by several powerful factors, including robust sales of its weight-loss drug Zepbound and diabetes drug Mounjaro, strong third-quarter financial results, and a recent government agreement regarding Medicare drug price negotiation.
